Menu Close

In 1 Day, 26 Leading Digital Health Professionals Share Critical Insights To Drive Forward Advances In Digital Health - Book A Virtual Pass Before This Thursday For Just £199* - SAVE £450! 

Europe's Digital Health Advances Virtual Conference For Pharma: Enhance Patient Outcomes, Boost Market Access & Improve Healthcare Delivery & Value In These Times Of Digital Acceleration & Advancement: Capitalise On The Opportunities In Digital Health, Telemedicine, Telehealth, Digital Therapeutics & Connected Devices To Improve Patient Outcomes With The Latest AI, ML, Digital & Tech Innovations, Real World Data & Future-Ready Regulatory Frameworks.

A One-Day, Virtual, Brand-Led Conference & Networking Event, 15th June 2021. Group Discounts Available - Send 4 For 3! Please call +44 (0)20 3479 2299. 

08.30 Registration, Coffee & Informal Networking

09.00 Co-Chairs’ Opening Remarks

Dr. David W Cottam, Senior Director, Associate General Patent Counsel, European Generics, Global Medical Devices & Digital Health, Teva Pharmaceuticals Ltd

Christian Tilmann, Director M&A & Corporate Development, Director Sales & Marketing, McKesson Europe AG


09.10 Assess How Covid-19 Has Fuelled Digital Health Advancements & Trends & Opportunities In Telehealth, Digital Therapeutics & Connected Devices To Determine How To Cement Long-Lasting Impact

  • The pandemic has forced attention to decentralised studies: ensure you are equipped with the right digital, tech and tools to run siteless trials effectively
  • How has Covid-19 accelerated the move to digital health and remote patient monitoring and changed the landscape of clinical research?
  • A look to the future: will we go back to old models post-pandemic or has this elicited long-lasting change?

Dr. Eddie Guzdar, Head of Medical - Neurology & Immunology UK & Ireland, Sanofi

David Braun, Global Head Of Connected Health & Device Solutions, Merck Group

Bodo Wiegand, Head of Market Access & Reimbursement CoE, Chief Medical Office, Philips Healthcare


09.40 The Next Generation Of Healthcare: Leverage The Acceleration Of Telemedicine & Increase In Telehealth Partnerships To Enhance Patient Outcomes & Drive Long-Lasting Changes Without Losing The Human Touch

  • Understand new reimbursement opportunities for telehealth and what the target usage of telehealth is beyond virtual video consultations and the pandemic
  • How will telemedicine and telehealth impact the current MedTech business models?
  • Overcome physician resistance and examine how teleconsultations have been received by all parties with tangible data and insights
  • How can we maintain momentum: maximise the major drivers of adoption from users that we can push once restrictions have been lifted

Bodo Wiegand, Head of Market Access & Reimbursement CoE, Chief Medical Office, Philips Healthcare


10.00 Maximise AI & ML To Improve Healthcare Delivery For A Competitive Advantage

  • Managing expectations: prove value and validate efforts with real data and insights captured from utilising AI & ML
  • What do HCPs and patients need to be aware of in the use of the new digital equipment, and what is the role of the human in AI?
  • Navigating regulatory frameworks: how are authorities proposing to navigate products with AI and ML which are constantly updating and changing by the second
  • AI, ML and RWD: what are the real business and performance outcomes taken from the data captured?

Hicham Naim, Global Integrated & Personalised Care Program Head, Takeda

Bonus Session: EXEEVO

10.20 Exeevo Case Study

Chris Wade, Associate Vice President, Strategic Solutions, Exeevo Inc

10.35 Morning Refreshment Break With Informal Networking


11.05 Strategies To Optimise Care Coordination Through Telemedicine

Prof. Michael Miller, WHO Digital Health Technical Advisory Group (DHTAG) Roster of Experts, The World Health Organization 

Digital Health Solutions & SaMD: Key Learnings For Successful Development & Launch

11.25 For companies looking to build digital health solutions, Software as a Medical Device (SaMD) is now an essential distinction to be aware of. Not all digital health solutions are classified as SaMD, so it’s important to be clear on the influencing factors and the implications of going down this path.

  • Why SaMD is important for digital health, the capabilities required, and the best approach when developing solutions
  • Assessing the medical device classification of solutions and how this impacts on your business strategy, development plan, and regulatory roadmap
  • Choosing the best region for launch and how it will determine the level of evidence and validation required, and what reimbursement models are available

Matt Norton, Vice President - Marketing & Commercial Development, S3 Connected Health


11.40 Is Data The Future Of Healthcare? Translate Data Into Actionable Insights To Drive Digital Health Innovations & Secure Strategic Success

  • Discover concrete examples of how we can access the value of real-world data and how to enrich the data from clinical studies with secondary data that is already there
  • Data responsibility and data protection: as the patient becomes responsible for their own data in the digital health models, how can we find new ways to compliantly transfer the data to generate insight
  • RWD and reimbursement schemes: how can you use patient data captured to visualise outcomes and use these insights to showcase results to stakeholders?

11.40 Perspective One
Rebecca Wray, Associate Director, Digital Health Oncology, AstraZeneca (UK)


12.00 Perspective Two
Laura Cirillo, Head of Digital & Innovation, AstraZeneca (Italy)


12.20 Lunch For Delegates, Speakers & Partners


12.25 Informal Lunchtime Discussions

A) Reimbursement
Rudiger Papsch, Global Market Access & HEOR Head Cardiology, Servier

B) Digitalisation Vs. Digital Products
Hicham Naim, Global Integrated & Personalised Care Program Head, Takeda

C) Digital Therapeutics & The Pharma World
Dario Motti, Principal Scientist - Digital Health Technologies, Roche

13.20 Chairs’ Opening Remarks

Pieter De Muynck, Country Commercial Director Immunology, Pulmonary Hypertension, CNS/VOT, Janssen


13.30 Capitalise On Cutting-Edge Digital & Tech Innovations For Integrated Strategies Which Improve Efficiencies

  • With Covid-19 fuelling a digital revolution in healthcare, ensure you have innovative, cutting-edge digital and tech to monitor and keep track of
    patients’ health from afar
  • A clinical evaluation of digital tools: what are the standards, what are the current regulatory landscapes, and what are the major roadblocks?
  • Overcome barriers to adoption and ensure you build a strategy around critical insights which prove value and secures buy-in for continued usage beyond coronavirus

Umair Aslam, Agile & Partnerships Lead – Digital & Customer Solutions, MSD Norway

Dr. Myles Furnace, Global Digital Health Lead Partnerships, Strategy, Transformation & Digital, IPSEN

Yannis Pandis, Digital Health Science & Technology Lead, Janssen Immunology

Romika Bhowmick, Associate Director, Commercial Platforms Strategy, Teva Pharmaceuticals

Dr. Sachin Shah, Global Medical Partner, Digital Health & Devices, GSK (Consumer Healthcare)

Keren Zimmerman, Head of Direct to Consumer, Happify Health

Dr. Tryggvi Thorgeirsson, Chief Executive Officer & Co-Founder, SidekickHealth


14.10 Drive Advances In Digital Health By Utilising Connected Devices & Evidenced Based Healthtech To Improve Patient Experience & Treatment

  • Qualification to classification: with more companies transitioning from wellbeing to healthcare devices and the introduction of new
    regulations, what does this mean for the market?
  • Examine the intersection between connected or digital devices and telemedicine to help consolidate future usage
  • Assess advances in connected device development and how to match the right formulation with the right device to push forward digital improvements
  • Gain critical insight into key regulatory considerations and recommendations with connected devices

David Braun, Global Head of Connected Health & Device Solutions, Merck Group


14.30 Equip Yourself With A Robust Framework To Suit Future Regulatory Challenges & Shifting Regulatory Routes To Market In Digital Health

  • In an ever-evolving field, examine the different levels of regulatory approval available for digital therapeutics and telehealth today, and how these compare to the current standards
  • MDR vs. MDD lessons learned: expert insight into how MDR is changing the regulatory market with tighter efficacy standards and how this impacts classification
  • Maximise collaboration! Establish meaningful, effective partnerships and work together to begin to obtain regulatory approval for digital health

Dario Motti, Principal Scientist - Digital Health Technologies, Roche

Sabrina Hueso, Head of Legal, Iberia, Allergan Aesthetics an AbbVie company

Priya Durvasula, Head, Global Quality, for Digital Health - International, Eli Lilly and Company

StarLeaf: Connecting Your Virtual Care Ecosystem

15.00 In this presentation you will learn how StarLeaf is connecting your virtual ecosystem like MDT rooms, remote patient care, virtual care workflows and many more.

Alex Robinson, Head of Public Sector, UK, StarLeaf

15.15 Afternoon Refreshment Break With Informal Networking


15.45 Drive Digital Therapeutics Forward & Showcase Its Commercial Value During These Times Of Digital Acceleration & Advancement

  • Drawing on insights gained during the pandemic, discover the new opportunities which have arisen due to Covid-19 and the resulting acceleration of changes in healthcare systems
  • How can digital therapeutics play into existing commercial models, and does it open up new reimbursement opportunities?
  • Secure a clearer understanding of current routes to market, and where the commercial success of digital therapeutics lies so far
  • How can digital therapeutics be used to improve patient engagement, effectiveness and experience?

15.45 Perspective One
Søren Smed Østergaard, Global VP Digital Health, Novo Nordisk A/S

16.05 Perspective Two
Dominick Kennerson, Global Head G4A - Digital Health Partnerships, Bayer


16.25 Optimise Patient Engagement In Digital Health Strategies With Meaningful Partnerships & Collaboration For Effective Market Access & Better Patient Outcomes

  • Beyond the pill! Examine opportunities in the patient journey to establish where pharma can most tangibly improve patient outcomes and commercial success
  • Determine the role and responsibility of the patient in digital health and care pathways in order to provide valuable patient education
  • Boost clinical outcomes and secure long-lasting patient-pharma partnerships by seizing opportunities with new, innovative patient engagement tools
  • How can we work closer with patients to ensure further adoption of digital therapeutics, new medical devices, apps and digital health to enrich patient outcomes?

Ömür Öztaş, Digital Innovation Lead Growth Markets, Emerging Markets, GSK

16.45 Chairs’ Closing Remarks

Pieter De Muynck, Country Commercial Director Immunology, Pulmonary Hypertension, CNS/VOT, Janssen

17.00 Official Close Of Conference


Global Insight Conferences is a rapidly-expanding and highly entrepreneurial conference company. We only employ individuals who are passionate about conferences, passionate about their personal growth and performance and passionate about being the best. Please send your CV with a covering letter to